INDP Indaptus Therapeutics, Inc.

Nasdaq indaptusrx.com


$ 3.61 nm (nm)    

Tuesday, 21-Oct-2025 15:59:51 EDT
QQQ $ 610.60 nm (nm)
DIA $ 469.43 $ 2.06 (0.44 %)
SPY $ 671.07 nm (nm)
TLT $ 92.00 nm (nm)
GLD $ 379.75 nm (nm)
$ 3.9
$ 3.82
$ 3.55 x 1,283
$ 3.99 x 25
$ 3.57 - $ 3.85
$ 2.22 - $ 58.24
106,832
na
4.32M
$ 1.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of t...

Core News & Articles

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The m...

 indaptus-reports-partial-response-from-decoy20-monotherapy-in-urothelial-cancer-combo-with-pd-1-inhibitor-shows-favorable-safety

Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastasesDecoy20 combination with PD-...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION